DS
Therapeutic Areas
Bayer Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Nubeqa® (darolutamide) | Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | Phase III |
| Kerendia® (finerenone) | Chronic Kidney Disease in Type 2 Diabetes | Phase III |
| Asundexian (BAY 2433334) | Stroke Prevention after Acute Non-Cardioembolic Ischemic Stroke | Phase III |
| BAY 2927088 | NSCLC with EGFR Mutations | Phase I/II |
| BAY 2666605 (JNJ-75276617) | Acute Myeloid Leukemia with NUP98 Rearrangements | Phase I |
| AAV-hFKRP (ASK-010) | Limb-Girdle Muscular Dystrophy Type 2I/R9 | Phase I/II |
| bri-cel (BAY 2413334) | Relapsed/Refractory Multiple Myeloma | Phase I |
| OpRegen® (RG6501) | Geographic Atrophy Secondary to AMD | Phase II |
Leadership Team at Bayer
BA
Bill Anderson
Chief Executive Officer
WN
Wolfgang Nickl
Chief Financial Officer
DC
Dr. Christian Rommel
Head of Research and Development, Pharmaceuticals
DR
Dr. Robert Reiter
Head of R&D, Crop Science
HS
Heiko Schipper
President, Consumer Health
OK
Oliver Kohlhaas
President, Pharmaceuticals International